Plain-English translation of NCT03827317 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Breast Cancer research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a new imaging scan called [18F]GE-226 PET that can light up HER2 protein in breast cancer tumors. Researchers want to see if this medication can reliably identify whether breast cancer tumors have high or low levels of HER2, which is important because HER2 status affects treatment decisions. The study will compare how well the new scan works in women whose cancers are HER2-positive versus HER2-negative.
Currently, doctors check HER2 status through tissue biopsies, which are invasive and can only sample one small area of a tumor. This medication offers a non-invasive way to scan your whole body and see HER2 levels throughout all your tumors, which could help doctors choose better, more personalized treatments.
You likely qualify if…
You likely don't qualify if…
You will receive an injection of the radioactive tracer, then lie still inside a PET imaging scanner for about 90 minutes while it takes pictures of your tumors. During the scan, doctors will draw blood samples from an artery in your wrist to measure how your body processes the medication. You will have blood tests and physical exams before and after to check for any side effects. The entire study involves one imaging visit, though you may have follow-up visits for safety monitoring.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United Kingdom
Sponsor
Imperial College London
Collaborators
Medical Research Council, University of Cambridge
Enrollment target
~24 participants
Started
March 2019
Primary completion
March 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Sex
Female only
Last updated on clinicaltrials.gov in August 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
HERPET Trial Coordinator
Imperial College London
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.